Prof. Dr. Thomas Herrmann
2021-2024
Phylogeny and species comparison as tools for understanding antigen recognition by human γδ T-cells
γδ T-cell antigen-receptors (γδTCR) emerged together with the other RAG-dependent antigen receptors and are found in nearly all jawed vertebrate species. There is an increasing interest in clinical use of γδTCR-expressing cells (γδ T-cells) but the antigens and the modes of antigenrecognition by γδ T-cell antigen-receptors (TCRs) are poorly understood. γδ T cells vary massively in phenotype and function and subpopulations of γδ T cells are found only in certain species and are often defined by their V-gene usage. One of those subpopulations are human Vγ9Vδ2 T cells whose eponymous TCRs sense so-called phosphoantigens (PAgs), which are phosphorylated host or microbial metabolites of isoprenoid synthesis. The strongest natural PAg is HMBPP which drives Vγ9Vδ2 T-cell-activation and -expansion in infections like tuberculosis and malaria. A rather weak and host cell-produced PAg is IPP which accumulates in some tumor cells or after treatment with amino-bisphosphonates (e.g. zoledronate). This IPP accumulation sensitizes the cells for the tumoricidal activity of Vγ9Vδ2 T-cells.
For more than 20 years Vγ9Vδ2 T-cells were believed to be restricted to higher primates but we found such cells in the alpaca although missing in murine rodents. Vγ9Vδ2 TCR do not bind PAgs directly but sense host cell changes induced by PAg -binding to the intracellular domain of BTN3A1 molecules. In humans BTN3A1 cooperates with its isoforms BTN3A2 and BTN3A3 while alpaca possesses a single BTN3 which integrates the functions of the three isoforms. Apart from BTN3A1, BTN2A1-expression by the target cells is also essential for PAg-mediated activation of Vγ9Vδ2 T cells. However, molecular events and signaling cascades involved in the TCR-mediated activation are poorly understood. We will create BTN3-chimeric molecules and mutants to identify minimal molecular requirements of PAg-sensing and to assign protein domains to certain function by analysis with biochemical and imaging techniques. Similarly, we will use species differences to investigate the interaction between BTN3 and BTN2A1 molecules
and that of BTNs and TCR.
In parallel TCR-BTN interaction shall be studied also in other species. To reconstruct TCR-BTN coevolution BTN-domains will be inserted into human molecules and tested for functionality. Compared will be BTNs and TCRs of human, alpaca, camels and the thirteen-lined squirrel, one of the few rodents possessing genes for BTN2, BTN3 and TCR-Vγ9. Finally, we want to learn whether Vγ9Vδ2 T-cells from different species, namely human, alpaca and Old-World camelids, share common features apart from their TCR. To this end transcriptomics of Vγ9Vδ2 T cells from different species will be performed aiming to understand what makes a Vγ9Vδ2 T-cell a Vγ9Vδ2 T cell apart from its TCR.
Prof. Dr. Thomas Herrmann
2018-2021
Phylogeny and Function of Vγ9Vδ2 T cells: Human vs. Camelids
Vγ9Vδ2 T cells are potent effectors of human immune responses against pathogens and tumors. Their T cell receptors (TCR) recognize small pyrophosphorylated molecules (phosphoantigens) which are products of isoprenoid-synthesis of host or microbes. This recognition requires expression of the cell surface molecule butyrophilin 3A1 (BTN3A1) and its isoforms BTN3A2 and BTN3A3 by the tumor or the antigen-presenting cell. With the exception of primates, most mammalian species including all small animal models lack BTN3 molecules and Vγ9Vδ2 T cells. We have demonstrated that genes for Vγ9Vδ2 TCR and BTN3 co-evolved with the emergence of placental mammals and that the new world camelid alpaca (Vicugna pacos) possesses phosphoantigen-specific Vγ9Vδ2 T cells and only a single BTN3 isoform. In this project we aim at understanding the molecular basis of BTN3 and Vγ9Vδ2 TCR function by analyzing and comparing camelid and human Vγ9Vδ2 T cells. Such knowledge will help to improve Vγ9Vδ2 T cell based therapies, e.g. by engineering cells with tumor specific Vγ9Vδ2 TCR or by modulating overshooting Vγ9Vδ2 T cell responses in infections. We plan to identify general structural features which allow Vγ9Vδ2 TCRs to respond to phosphoantigens and commonalities of Vγ9Vδ2 T cells beyond expression of the Vγ9Vδ2 TCR. To this end we will compare Vγ9Vδ2 TCR in phosphoantigen-responses of alpaca and human blood lymphocytes and gene expression profiles (transcriptomes) between Vγ9Vδ2 T cells of both species. Sites mandatory for BTN3 function and the BTN3/TCR interaction as well as for interaction between BTN3 isoforms will be identified by testing the reactivity of alpaca and human molecule chimeras and BTN3 and TCR mutants with help of newly generated reporter cell lines. Finally, we want to use our expertise in camelid γδ T cells for the analysis of the enigmatic somatic hypermutation (SHM) within γδ TCRs of the dromedary (Camelus dromedarius). Here we aim to learn whether SHM serves as mechanism to increase γδ TCR diversity during γδ T cell development in the thymus or to increase affinity of γδ TCR (antigen receptor) analogous to affinity maturation of antibody producing B cells. As part of the FOR2799 (”Receiving and Translating Signals via the γδ T Cell Receptor”) the project will benefit and contribute from the collaborations with the other projects and finally provide a better insight into the role of γδ T cells in anti-tumor and anti-viral immunity.
